Keyphrases
Anticancer Drug Exposure
28%
C-reactive Protein
100%
Clinical Data
14%
Disease Evolution
14%
Drug Resistance
14%
Dynamic Biomarkers
100%
Early Predictors
100%
Early Progression
14%
Efficacy Predictor
100%
First-line Chemotherapy
14%
Immunotherapy Therapy
14%
Inflammatory Activity
14%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Longitudinal Biomarker
14%
Longitudinal Predictors
14%
Modeling Framework
100%
Non-small Cell Lung Cancer Patients
100%
NONMEM
14%
Oncology
14%
Oncology Drug Development
14%
Overall Survival
28%
Patient Identification
14%
Patient Response
14%
Patient Status
14%
Patients at Risk
14%
Predictors of Progression
28%
Prognostic Marker
14%
Progression-free Survival
28%
Protein Concentration
57%
Protein Production
14%
RECIST Criteria
14%
Reliability Prediction
14%
Response to Treatment
14%
Strong Predictor
14%
Targeted Therapy
14%
Time-to-event Model
14%
Timely Identification
14%
Treatment Cycle
42%
Treatment Decisions
14%
Treatment Modalities
14%
Tumor Dynamics
100%
Tumor Size
28%
Turnover Model
14%
Pharmacology, Toxicology and Pharmaceutical Science
Anticarcinogen
28%
Biological Marker
100%
C Reactive Protein
100%
Disease Course
14%
Drug Resistance
14%
First-Line Chemotherapy
14%
Immunotherapy
14%
Neoplasm
100%
Non Small Cell Lung Cancer
100%
Overall Survival
28%
Progression Free Survival
28%
Biochemistry, Genetics and Molecular Biology
Anticancer
28%
C-Reactive Protein
100%
Drug Development
14%
Drug Exposure
28%
Drug Resistance
14%
Dynamics
100%
Overall Survival
28%
Progression Free Survival
28%
Targeted Therapy
14%
Tumor Volume
28%